BRCA1 and BRCA2 are tumour-suppressor genes encoding proteins that are essential for
the repair of DNA double-strand breaks by homologous recombination (HR). Cells that lack …

Objective The role of BRCA dysfunction on the prognosis of patients with epithelial ovarian
cancer (EOCs) remains controversial. This systematic review tried to assess the role of …

Purpose: Approximately 5–10% of patients who undergo genetic testing of BRCA1 and
BRCA2 receive a variant of unknown significance (VUS) result. The ambiguous nature of a …

Pathogenic germline BRCA1, BRCA2 (BRCA1/2), and several other gene variants
predispose women to primary ovarian, fallopian tube, and peritoneal carcinoma (OC) …

Ovarian cancer (OC) mostly arises sporadically, but a fraction of cases are associated with
mutations in BRCA1 and BRCA2 genes. The presence of a BRCA mutation in OC patients …

Overview Ovarian cancer is one of the most treatable solid tumors, as the majority will
respond temporarily to surgery and cytotoxic agents. The disease, however, frequently …

Introduction One of the most significant risk factors for the development of ovarian cancer
(OC) is a genetic mutation in BRCA1 (breast cancer gene 1) or BRCA2. Here we describe …

Constitutional loss-of-function pathogenic variants in the tumor suppressor genes BRCA1
and BRCA2 are widely associated with an elevated risk of ovarian cancer (OC). As only …

Background and Objectives: Approximately 10–15% of high-grade serous ovarian cancer
(HGSOC) cases are related to BRCA germline mutations. Better survival rates and increased …

The overall prevalence of germline BRCA 1/2 mutations is estimated between 11% and 15%
of all ovarian cancers. Individuals with germline BRCA 1/2 alterations treated with the PARP …